New radiation approach aims to shrink pancreatic tumors in just five sessions
NCT ID NCT05191940
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a short, high-dose radiation therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The treatment uses protons or carbon ions to deliver a precise, powerful dose in only five sessions. Researchers hope this approach will improve tumor control while reducing the number of hospital visits.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Proton or carbon ion radiation therapy
- What this could lead to
- If successful, this could offer a more convenient and effective radiation option for patients with inoperable pancreatic cancer, potentially improving local tumor control.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. High-dose radiation also carries risks of damage to nearby organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2022
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. The patient has histologically or cytological confirmed diagnosis of pancreatic cancer (cases with radiological findings suspicious of pancreatic cancer AND elevated CA 19-9 may be enrolled even without positive cytology) 2. The patient is not candidate for radical surgical resection because of one or more of the following reasons: 1. the patient is staged as locally advanced and with unresectable disease according to the international consensus definition. Specific criteria are: there is involvement of portal vein/superior mesenteric vein with bilateral narrowing/occlusion, exceeding the inferior border of the duodenum; or tumor contact/invasion of 180 or more degree of the superior mesenteric artery or of the truncus coeliacus; or tumor contact/invasion of the proper hepatic artery/ celiac artery; or tumor contact or invasion of the aorta. 2. the patient is not a candidate for radical surgery because of radiographic or biochemical (CA 19-9) progression during neoadjuvant chemotherapy despite being initially classified as resectable or borderline resectable according to the international consensus definition. 3. the patient is not candidate for radical surgery because of cN+ stage 3. The patient is not candidate to (further) neoadjuvant chemotherapy because of one or more of the following reasons: 1. the patient is not fit for chemotherapy 2. the patient has progressed under chemotherapy 3. the patient has received neoadjuvant chemotherapy but is judged still not a candidate for explorative surgery. 4. Negative staging for distant metastasis 5. Age \> 18 years 6. Karnofsky index ≥ 70 7. No tumor infiltration of stomach or duodenum 8. The patient is informed of the diagnosis and is able to give informed consent (Ability of patient to understand character and individual consequences of the study protocol) 9. Women of fertile age must have adequate conception prevention measures and must not breast feed 10. Signed Informed Consent (must be available before study inclusion) Exclusion Criteria: 1. Non-exocrine tumors 2. Major medical or psychiatric comorbidities that contraindicate radiotherapy 3. Presence of distant metastasis 4. Pregnancy or unwilling to do adequate conception prevention 5. Lactating and unwilling to discontinue lactation 6. Men of procreative potential not willing to use effective means of contraception 7. Metallic prosthesis or other conditions - IF it prevents an adequate imaging for target volume definition or treatment planning at the discretion of the treating institution contraindicate radiotherapy e.g. active infections in the area 8. Previous abdominal radiotherapy 9. Severe hepatic or renal impairment at discretion of treating institution 10. Patient refusal
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Locally advanced pancreatic cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
EBG MedAustron GmbH
RECRUITINGWiener Neustadt, Lower Austria, 2700, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Gut bacteria may hold clues to why some cancer treatments work better
- Two oral drugs join chemotherapy in a bid to shrink pancreatic tumors
- New antibody aims to preserve immune checkpoint while fighting cancer
- Can acupuncture soothe Chemotherapy's lingering nerve pain?
- Can chemo before surgery extend lives in pancreatic cancer?